DIAGNOS and ÉTS Unveil a Method to Adapt Deep Learning Algorithms According to the Diversity of Contexts
01 March 2023 - 1:00AM
Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture:
ADK) (OTCQB: DGNOF) is one of the leaders in early detection of
critical health issues through the use of its FLAIRE platform based
on Artificial Intelligence (AI). DIAGNOS and École de Technologie
Supérieure (ÉTS), a world-renowned technical university, are proud
to announce the unveiling of a method for adapting deep learning
algorithms according to the diversity of contexts, in diabetic
retinopathy screening.
DIAGNOS and ÉTS conducted research to improve
the performance of DIAGNOS’ deep learning algorithms in situations
known to cause the degradation of learning models, particularly
when the solutions are implemented in different contexts, such as
in new healthcare facilities, when using new retinal cameras, or
with patient cohorts with unusual demographic characteristics. In
Deep Learning, degradation of the learning models occurs when the
data utilized to train the model differs from the data it
encounters in real-world applications, which is when adaptation
methods, such as those developed by DIAGNOS and ÉTS become
useful.
The proposed method uses samples from the new
contexts to refine the algorithms. It has proven to be a very
effective solution for improving the performance of learning
models. This new method brings significant improvement, so much so
that the Association for Research in Vision and Ophthalmology
(ARVO) elected to provide a platform to DIAGNOS and ÉTS at ARVO
2023 so that researchers, practitioners, and industry stakeholders
can learn about the proposed method and its major positive impacts
on the field of medical imaging.
"Data is at the heart of everything we do at
DIAGNOS. This new method of domain adaptation allows us to rapidly
train our deep learning models with diverse data sources, while
maintaining and improving accuracy, making our diabetic retinopathy
screening solutions more effective and versatile than ever before.
We eagerly anticipate the presentation of our findings at ARVO
2023" – Mr. Riahd Kobbi, Vice-President of Business
Intelligence at DIAGNOS.
“At DIAGNOS, we always push the boundaries of
innovation. Our latest research with ÉTS represents another step
forward in our mission to improve the accuracy and speed of
diabetic retinopathy screening, particularly in new and challenging
environments”, said Mr. André Larente, President of
DIAGNOS. “As we prepare to implement our solutions into
hundreds of new sites, this domain adaptation method comes at just
the right time. By using deep learning algorithms and innovative
domain adaptation techniques, we are able to provide accurate and
efficient diabetic retinopathy screening solutions that can be
adapted to a wide range of clinical settings, thus providing huge
benefits to our clients."
DIAGNOS also announces that Dr. Reid Maclelland
has resigned from the board of directors of the Corporation. We
would like to thank Dr. Maclelland for his valuable support over
his term and wishes him well in his future endeavors.
About ARVOThe Association for Research in Vision
and Ophthalmology (ARVO) is the largest eye and vision research
organization in the world. Members include approximately 10,000 eye
and vision researchers from over 75 countries. ARVO advances
research worldwide into understanding the visual system and
preventing, treating, and curing its disorders. The ARVO annual
conference is a premier event in the field of vision research,
bringing together scientists, clinicians, and industry
professionals from around the world to share their latest findings
and innovations. The conference will take place between April 23rd
and 27th, in New Orleans.
Additional information is available at
www.arvo.org
About ÉTS
École de technologie supérieure is one of ten
constituents of the Université du Québec network. It trains
engineers and researchers who are recognized for their practical
and innovative approach, the development of new technologies and
their skill at transferring their knowledge to companies. Almost
one-quarter of all engineers in Québec graduated from ÉTS, which
boasts 11,000 students, including 2,650 at the graduate and
post-graduate level. ÉTS specializes in applied training and
research in engineering, and maintains a unique partnership with
the business sector and with industry.
Additional information is available at
www.etsmtl.ca
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based on its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients. CARA has been
cleared for commercialization by the following regulators: Health
Canada, the FDA (USA) and Saudi FDA (Saudi Arabia).
Additional information is available at
www.DIAGNOS.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS Inc.Tel: 450
678-8882, ext. 224Email: alarente@DIAGNOS.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
An image accompanying this announcement is
available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/104307da-ae68-442a-8e20-369d572b6083
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024